GeneReach Biotechnology Corp. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 54.38 million compared to TWD 323.42 million a year ago. Revenue was TWD 54.26 million compared to TWD 323.25 million a year ago. Net loss was TWD 46.01 million compared to net income of TWD 137.16 million a year ago. Basic loss per share from continuing operations was TWD 0.8 compared to basic earnings per share from continuing operations of TWD 2.39 a year ago. Diluted loss per share from continuing operations was TWD 0.8 compared to diluted earnings per share from continuing operations of TWD 2.34 a year ago.
For the six months, sales was TWD 122.6 million compared to TWD 559.15 million a year ago. Revenue was TWD 122.45 million compared to TWD 558.93 million a year ago. Net loss was TWD 83.32 million compared to net income of TWD 236.98 million a year ago. Basic loss per share from continuing operations was TWD 1.45 compared to basic earnings per share from continuing operations of TWD 4.12 a year ago. Diluted loss per share from continuing operations was TWD 1.45 compared to diluted earnings per share from continuing operations of TWD 4.02 a year ago.